169 related articles for article (PubMed ID: 38276867)
1. Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer.
Roper N; El Meskini R; Maity T; Atkinson D; Day A; Pate N; Cultraro CM; Pack S; Zgonc V; Weaver Ohler Z; Guha U
Cancer Res Commun; 2024 Feb; 4(2):337-348. PubMed ID: 38276867
[TBL] [Abstract][Full Text] [Related]
2. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Sequist LV; Han JY; Ahn MJ; Cho BC; Yu H; Kim SW; Yang JC; Lee JS; Su WC; Kowalski D; Orlov S; Cantarini M; Verheijen RB; Mellemgaard A; Ottesen L; Frewer P; Ou X; Oxnard G
Lancet Oncol; 2020 Mar; 21(3):373-386. PubMed ID: 32027846
[TBL] [Abstract][Full Text] [Related]
3. MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC.
Haratake N; Ozawa H; Morimoto Y; Yamashita N; Daimon T; Bhattacharya A; Wang K; Nakashoji A; Isozaki H; Shimokawa M; Kikutake C; Suyama M; Hashinokuchi A; Takada K; Takenaka T; Yoshizumi T; Mitsudomi T; Hata AN; Kufe D
J Thorac Oncol; 2024 Mar; 19(3):434-450. PubMed ID: 37924972
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation-Positive, MET-Amplified Non-Small Cell Lung Cancer Model.
Jones RDO; Petersson K; Tabatabai A; Bao L; Tomkinson H; Schuller AG
Mol Cancer Ther; 2023 May; 22(5):679-690. PubMed ID: 36888921
[TBL] [Abstract][Full Text] [Related]
5. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
[TBL] [Abstract][Full Text] [Related]
6. P21-activated kinase 2-mediated β-catenin signaling promotes cancer stemness and osimertinib resistance in EGFR-mutant non-small-cell lung cancer.
Yi Y; Li P; Huang Y; Chen D; Fan S; Wang J; Yang M; Zeng S; Deng J; Lv X; Luo K; He Z; Liu H
Oncogene; 2022 Sep; 41(37):4318-4329. PubMed ID: 35986102
[TBL] [Abstract][Full Text] [Related]
7. MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinib.
Nishiyama A; Takeuchi S; Adachi Y; Otani S; Tanimoto A; Sasaki M; Matsumoto S; Goto K; Yano S
Cancer Sci; 2020 Oct; 111(10):3813-3823. PubMed ID: 32735723
[TBL] [Abstract][Full Text] [Related]
8. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
[TBL] [Abstract][Full Text] [Related]
9. Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).
Martinez-Marti A; Felip E; Matito J; Mereu E; Navarro A; Cedrés S; Pardo N; Martinez de Castro A; Remon J; Miquel JM; Guillaumet-Adkins A; Nadal E; Rodriguez-Esteban G; Arqués O; Fasani R; Nuciforo P; Heyn H; Villanueva A; Palmer HG; Vivancos A
Ann Oncol; 2017 Oct; 28(10):2451-2457. PubMed ID: 28961841
[TBL] [Abstract][Full Text] [Related]
10. The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via direct MET inhibition.
Chen Z; Vallega KA; Chen H; Zhou J; Ramalingam SS; Sun SY
Pharmacol Res; 2022 Jan; 175():105998. PubMed ID: 34826601
[TBL] [Abstract][Full Text] [Related]
11. Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in
Namba K; Shien K; Takahashi Y; Torigoe H; Sato H; Yoshioka T; Takeda T; Kurihara E; Ogoshi Y; Yamamoto H; Soh J; Tomida S; Toyooka S
Mol Cancer Res; 2019 Feb; 17(2):499-507. PubMed ID: 30463991
[TBL] [Abstract][Full Text] [Related]
12. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in
Okura N; Nishioka N; Yamada T; Taniguchi H; Tanimura K; Katayama Y; Yoshimura A; Watanabe S; Kikuchi T; Shiotsu S; Kitazaki T; Nishiyama A; Iwasaku M; Kaneko Y; Uchino J; Uehara H; Horinaka M; Sakai T; Tanaka K; Kozaki R; Yano S; Takayama K
Clin Cancer Res; 2020 May; 26(9):2244-2256. PubMed ID: 31953310
[TBL] [Abstract][Full Text] [Related]
13. Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies.
Leonetti A; Verzè M; Minari R; Perrone F; Gnetti L; Bordi P; Pluchino M; Nizzoli R; Azzoni C; Bottarelli L; Lagrasta CAM; Mazzaschi G; Buti S; Gasparro D; Cosenza A; Ferri L; Majori M; De Filippo M; Ampollini L; La Monica S; Alfieri R; Silini EM; Tiseo M
Br J Cancer; 2024 Jan; 130(1):135-142. PubMed ID: 37938348
[TBL] [Abstract][Full Text] [Related]
14. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.
Oxnard GR; Yang JC; Yu H; Kim SW; Saka H; Horn L; Goto K; Ohe Y; Mann H; Thress KS; Frigault MM; Vishwanathan K; Ghiorghiu D; Ramalingam SS; Ahn MJ
Ann Oncol; 2020 Apr; 31(4):507-516. PubMed ID: 32139298
[TBL] [Abstract][Full Text] [Related]
15. Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an
Nishihara S; Yamaoka T; Ishikawa F; Ohmori T; Ando K; Kusumoto S; Kishino Y; Manabe R; Hasebe Y; Sagara H; Yoshida H; Tsurutani J
Cells; 2022 Jul; 11(14):. PubMed ID: 35883645
[TBL] [Abstract][Full Text] [Related]
16. AXIN1/MYC Axis Mediated the Osimertinib Resistance in EGFR Mutant Non-Small Cell Lung Cancer Cells.
Yu H; Wang Z; Dong Y; Li L; Fan X; Zheng N; Jiang J; Lin C; Lu C; Li K; Feng M
Tohoku J Exp Med; 2024 May; 262(4):269-276. PubMed ID: 38233113
[TBL] [Abstract][Full Text] [Related]
17. ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts.
Hu B; Wiesehöfer M; de Miguel FJ; Liu Z; Chan LH; Choi J; Melnick MA; Arnal Estape A; Walther Z; Zhao D; Lopez-Giraldez F; Wurtz A; Cai G; Fan R; Gettinger S; Xiao A; Yan Q; Homer R; Nguyen DX; Politi K
Cancer Res; 2024 Apr; 84(8):1303-1319. PubMed ID: 38359163
[TBL] [Abstract][Full Text] [Related]
18. Response to osimertinib plus trametinib in a heavily treated epidermal growth factor receptor (EGFR)-positive NSCLC harboring a rare, acquired rapidly accelerated fibrosarcoma B-type (BRAF) p.D594N mutation: a case report.
Li S; Lin X; Sun S; Li S; Zhou C
Anticancer Drugs; 2022 Oct; 33(9):963-965. PubMed ID: 36136993
[TBL] [Abstract][Full Text] [Related]
19. Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib.
Wang Y; Li L; Han R; Jiao L; Zheng J; He Y
Lung Cancer; 2018 Apr; 118():105-110. PubMed ID: 29571987
[TBL] [Abstract][Full Text] [Related]
20. Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer.
Cai X; Miao J; Sun R; Wang S; Molina-Vila MA; Chaib I; Rosell R; Cao P
Pharmacol Res; 2021 Aug; 170():105701. PubMed ID: 34087353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
